Trial Profile
A Phase 3, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with Abatacept in Subjects with Active Crohn's Disease (CD) who have had an Inadequate Clinical Response and/or Intolerance to Medical Therapy
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 03 Aug 2022
Price :
$35
*
At a glance
- Drugs Abatacept (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Pharmacogenomic; Pharmacokinetics; Registrational; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 31 Jul 2022 This trial has been completed in Germany (End Date: 12 Aug 2009), according to European Clinical Trials Database record.
- 04 Jul 2012 Additional trial locations added as reported by European Clinical Trials Database.
- 04 Jul 2012 Planned number of patients changed from 689 to 906 as reported by European Clinical Trials Database.